Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Aradigm Announces Fourth Quarter 2012 and Full Year Financial Results
Mar 26, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2012 . Fourth Quarter 2012 Results The Company recorded $223,000 in revenue in the fourth quarter of 2012 compared with
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2013 on February 12
Feb 06, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 15 th Annual BIO CEO & Investor Conference 2013 on Tuesday, February 12, 2013 , at 2:00 p.m. ET .
Aradigm to Present at Biotech Showcase 2013 on January 9
Jan 03, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at Biotech Showcase 2013 on Wednesday, January 9, 2013 , at 11: 00 a.m. Pacific time.
Aradigm Announces Private Placement for $6 Million
Dec 12, 2012
Proceeds Will Further Development of Inhaled Ciprofloxacin for the Treatment of Severe Respiratory Diseases HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it has entered into a definitive agreement for the sale of common stock to two
UK Scientists Report on Efficacy of Aradigm's Lipoquin™ Against Pneumonic Plague
Nov 19, 2012
A Single Dose of Aradigm's Liposomal Ciprofloxacin Delivered 24 Hours Post-Exposure with a Lethal Dose of Plague Provided Full Protection HAYWARD, Calif. --(BUSINESS WIRE)-- Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have
Aradigm Announces Third Quarter 2012 Financial Results
Nov 08, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2012 . Total revenue was approximately $0.3 million for the third quarter of 2012 compared with revenue of
Virginia Commonwealth University Scientists Report Anti-Inflammatory Effect of Aradigm's Inhaled Liposomal Ciprofloxacin
Oct 16, 2012
Major Inflammation Stimulating Factor Produced During Serious Lung Infections Inhibited by Aradigm's Drug HAYWARD, Calif. --(BUSINESS WIRE)-- Today at the annual meeting of the American Association of Pharmaceutical Scientists (AAPS) in Chicago, IL , scientists from the Virginia Commonwealth
UK Scientists Report Successful Testing of Aradigm's Inhaled Liposomal Ciprofloxacin in Q Fever
Sep 20, 2012
Q Fever is a Highly Infectious and Life Threatening Infection HAYWARD, Calif. --(BUSINESS WIRE)-- UK scientists from the Health Protection Agency (HPA) and Defence Science and Technology Laboratory (Dstl) reported this week at the University of Southampton's Wessex Life Sciences Alliance Conference
New U.S. Composition of Matter Patent for Aradigm's Pulmaquin™ and Lipoquin™ Provides Protection Until 2031
Sep 18, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB: ARDM) (" Aradigm " or the "Company") today announced that the United States Patent and Trademark Office has issued an important new composition of matter patent (U.S. Patent No. 8,268,347) to Aradigm for formulations of liposomal and
Aradigm Patent Protection for Smoking Cessation is Extended with Issuance of a Method of Treatment Patent
Sep 05, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB: ARDM) ("Aradigm" or the "Company") today announced that the United States Patent and Trademark Office has issued an important method of treatment patent (U.S. Patent No. 8,256,433) covering Systems and Methods for Effecting Cessation
Aradigm to Participate in FDA Workshop on Non-Cystic Fibrosis Bronchiectasis
Aug 30, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Igor Gonda , PhD., Aradigm's President and CEO, will be a panel member at the U.S. Food and Drug Administration's public workshop regarding the design of clinical trials of antibacterial drugs
Aradigm to Present at the Stifel Nicolaus 2012 Healthcare Conference
Aug 29, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Nancy E. Pecota , Aradigm's Vice President, Finance and Chief Financial Officer, will present an overview of the Company at the Stifel Nicolaus 2012 Healthcare Conference at the Four Seasons
Aradigm Announces Second Quarter 2012 Financial Results
Aug 09, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2012 . Total revenue was approximately $0.2 million for both the second quarter of 2012 and the second quarter of 2011.
Aradigm Announces First Quarter 2012 Financial Results
May 11, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2012 . Total revenue was $0.3 million for the first quarter of 2012, compared with $0.2 million in revenue for the first
Aradigm Announces Fourth Quarter 2011 and Full Year Financial Results
Mar 27, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2011 . The Company recorded $183,000 in revenue in the fourth quarter of 2011 compared with $144,000 in revenue in the
Aradigm Receives U.S. FDA Clearance for Phase 3 Clinical Trial of Pulmaquin™ in Patients with Non-Cystic Fibrosis Bronchiectasis
Mar 12, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or the "Company") today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis
US Patent Protection for Pulmaquin™ Is Extended with Issuance of a Composition of Matter Patent
Feb 21, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB: ARDM) ("Aradigm" or the "Company") today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 8,119,156) covering formulations of liposomal and free
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2012 on February 13
Feb 08, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 14 th Annual BIO CEO & Investor Conference 2012 on Monday, February 13, 2012 , at 2:30 p.m. ET .
Aradigm to Present at Biotech Showcase 2012 on January 9
Jan 05, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at Biotech Showcase 2012 on Monday, January 9, 2012 , at 11: 00 a.m. Pacific time.
Aradigm Selects Pulmaquin™ for Phase 3 Development and Announces Issuance of Its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations
Dec 07, 2011
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (" Aradigm " or the "Company") today announced that the United States Patent and Trademark Office has issued an important patent (U.S. Patent No. 8,071,127) regarding formulations of inhaled liposomal and free ciprofloxacin
Displaying 81 - 100 of 233
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.